cholecalciferol has been researched along with Prurigo* in 2 studies
1 review(s) available for cholecalciferol and Prurigo
| Article | Year |
|---|---|
Prurigo nodularis: a review.
Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology. This condition is a difficult disease to treat and causes frustration to both the patient and the treating doctor. A variety of systemic conditions have been reported to be associated with prurigo nodularis. The mechanism by which these disorders may trigger prurigo nodularis is unknown. Nerve growth factor has been implicated in the pathogenesis of prurigo nodularis. Calcitonin gene-related peptide and substance P immunoreactive nerves are markedly increased in prurigo nodularis when compared with normal skin. These neuropeptides may mediate the cutaneous neurogenic inflammation and pruritus in prurigo nodularis. Topical or intralesional glucocorticoids are the treatment of choice. Other topical treatments such as topical vitamin D3, and topical capsaicin have also been reported to be effective. Oral treatments such as cyclosporin and thalidomide have been shown to improve both appearance of the skin and pruritus. We review the clinical features, associations, pathology, pathogenesis and treatment of prurigo nodularis. Topics: Administration, Topical; Antipruritics; Capsaicin; Cholecalciferol; Combined Modality Therapy; Cryotherapy; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Mast Cells; Nerve Growth Factor; Neuropeptides; Prurigo; Thalidomide; Treatment Outcome; Ultraviolet Therapy | 2005 |
1 other study(ies) available for cholecalciferol and Prurigo
| Article | Year |
|---|---|
Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo.
A topical vitamin D3 ointment (tacalcitol) was prescribed for patients with long-lasting pruriginous lesions (four with prurigo nodularis and seven with subacute prurigo, four of whom had atopic dermatitis). Seven of 11 cases had not responded to a topical steroid ointment and even to occlusive application of the ointment. Nine of 11 cases showed a significant clinical response to this new regimen within 4 weeks. Epidermal Fc epsilon R1(+) dendritic cells were increased in number in prurigo nodularis and reduced to normal level after the therapy. Topical vitamin D3 ointment might be an alternative therapy for steroid-resistant prurigo. Topics: Administration, Topical; Adult; Aged; Cell Adhesion Molecules; Cholecalciferol; Drug Resistance; Female; Humans; Immunohistochemistry; Male; Middle Aged; Prurigo; Skin | 1996 |